ライフサイエンスコーパス: adrenergic receptor antagonist

1 phages were prevented by propranolol, a beta-adrenergic receptor antagonist.

2 further inhibited by yohimbine, an alpha(2A)-adrenergic receptor antagonist.

3 ion of PI 3-kinase in the presence of a beta adrenergic receptor antagonist.

4 response was blocked by prazosin, an alpha 1-adrenergic receptor antagonist.

5 ents with current or previous use of alpha-1 adrenergic receptor antagonists.

6 alterations of affinity values for selective adrenergic receptor antagonists.

7 Pretreatment with beta-adrenergic receptor antagonists abolished differences in

8 c hyperplasia is commonly treated with alpha-adrenergic-receptor antagonists (alpha-blockers) or 5alp

9 rtan (10 mg/kg b.wt) nor prazosin, an alpha1 adrenergic receptor antagonist, at doses of 5 microg/5 m

10 For many years, beta-adrenergic receptor antagonists (beta-blockers or betaAR

11 patients have shown that treatment with beta-adrenergic receptor antagonists (betaB) improves cardiac

12 Cotreatment with a beta2-adrenergic receptor antagonist, butoxamine, suggests tha

13 The data also suggest that beta-adrenergic receptor antagonists can attenuate LPS-induce

14 anolol or nadolol or the alpha1- + beta1,2,3-adrenergic receptor antagonist carvedilol before or afte

15 riment examined whether prazosin, an alpha 1-adrenergic receptor antagonist, could attenuate NMDA-ind

16 ression, but pre-exposure to timolol, a beta-adrenergic receptor antagonist, delayed this effect.

17 agonist, or propranolol, a nonselective beta-adrenergic receptor antagonist, delivered by osmotic pum

18 prevented with either LTCC blockers or beta-adrenergic receptor antagonists, demonstrating a proxima

19 Pretreatment with a beta-adrenergic receptor antagonist, esmalol, had no effect o

20 The affinity of selective alpha(1b)-adrenergic receptor antagonists for the switch mutant (D

21 Beta adrenergic receptor antagonists greatly reduce reactive

22 More recently, beta-adrenergic receptor antagonists have been found to provi

23 ceptor antagonist phentolamine nor the beta2-adrenergic receptor antagonist ICI 118, 551 antagonized

24 s repeated after administration of the beta2-adrenergic receptor antagonist ICI 118,551 (0.2 mg/kg).

25 al peritonitis with dopexamine and the beta2-adrenergic receptor antagonist ICI 118,551 (n = 4), ceca

26 ked by administration of the selective beta2-adrenergic receptor antagonist ICI-118,551.

27 as prevented by prior injection of the beta2-adrenergic receptor antagonist ICI-118,551.

28 is before and during infusion of the alpha 2-adrenergic receptor antagonist idazoxan (1.0 microgram.k

29 d the proepileptogenic actions of the alpha2 adrenergic receptor antagonist idazoxan.

30 responses can be inhibited by alpha and beta-adrenergic receptor antagonists implying a bacterial rec

31 Most clinical studies have shown that beta-adrenergic receptor antagonists improve long-term surviv

32 ls testing rho-kinase inhibitors and alpha2c-adrenergic receptors antagonists in vasospastic conditio

33 Neither norepinephrine nor adrenergic receptor antagonist infusion into the auditor

34 Only beta(1)-adrenergic receptor antagonists inhibited encystation, a

35 cocktail of alpha(1)-, beta(1)-, and beta(2)-adrenergic receptor antagonists into the mPFC prior to e

36 Orthosteric beta-adrenergic receptor antagonists, known as beta-blockers,

37 Systemic application of beta-adrenergic receptor antagonists may have detrimental eff

38 Here, we asked whether a beta-adrenergic receptor antagonist might interfere with the

39 Intraamygdala injections of a beta-adrenergic receptor antagonist or agonist, each timed to

40 ecursor, or with S(-) pindolol, a 5HT1A/beta adrenergic receptor antagonist or with LY206130, a more

41 h saline, phentolamine, a nonselective alpha-adrenergic receptor antagonist, or propranolol, a nonsel

42 effect was completely reversed by the alpha-adrenergic receptor antagonist phentolamine (i.p. and i.

43 4 h or by intravenous infusion of the alpha-adrenergic receptor antagonist phentolamine for only 30

44 the SPGN terminal, because neither the alpha-adrenergic receptor antagonist phentolamine nor the beta

45 Treatment of mice with the alpha-adrenergic receptor antagonist phentolamine prevented no

46 Treatment with alpha-adrenergic receptor antagonists potentiated dopamine inh

47 The alpha1-adrenergic receptor antagonist prazosin (0.1 microM) blo

48 l fear conditioning, injections of the alpha-adrenergic receptor antagonist prazosin (1.0 or 3.0 mg/k

49 urrent to 5.9 nM, and addition of the alpha1-adrenergic receptor antagonist prazosin did not cause an

50 tions in MA but not in MV while the alpha(1)-adrenergic receptor antagonist, prazosin (0.1 microm), b

51 Pretreatment with the alpha(1)-adrenergic receptor antagonist, prazosin, and the alpha(

52 The specific alpha(1)-adrenergic receptor antagonist, prazosin, inhibited the

53 Thy-1 mRNA levels were prevented by the beta-adrenergic receptor antagonist propranolol (10 microM).

54 30 mug) or vehicle (Experiment 1), the beta-adrenergic receptor antagonist propranolol (2 mug) or ve

55 ocked the effects of NA on Ito, but the beta-adrenergic receptor antagonist propranolol (20 microM) d

56 We find that administration of the beta-adrenergic receptor antagonist propranolol before memory

57 lthy participants were administered the beta-adrenergic receptor antagonist propranolol or a placebo

58 t, treatment before hemorrhage with the beta-adrenergic receptor antagonist propranolol was associate

59 The beta-adrenergic receptor antagonist propranolol, administered

60 D2 antagonist spiperone but not by the beta-adrenergic receptor antagonist propranolol.

61 ubjected to the nonselective (beta1 + beta2) adrenergic receptor antagonists propranolol or nadolol o

62 bsence of a alpha2-agonist (clonidine), beta-adrenergic receptor antagonist (propranolol), and beta(1

63 Although the beta-adrenergic receptor antagonist (-)-propranolol binds wit

64 ctivity was completely blocked by the alpha2-adrenergic receptor antagonist rauwolscine and by Clostr

65 ystment was inhibited by addition of beta(1)-adrenergic receptor antagonist to cells that were stimul

66 ies is also enhanced by administering a beta-adrenergic receptor antagonist to mice housed at 22 degr

67 nmol/L) or beta2- (ICI 118,551, 100 nmol/L) adrenergic receptor antagonist was also examined.

68 xed beta(1)/beta(2)- (timolol, metipranolol) adrenergic receptor antagonists were all shown to attenu

69 an melanocyte cell cultures with the alpha-2 adrenergic receptor antagonist yohimbine results in a ma

70 1 (CRF1) antagonist (antalarmin), and alpha2-adrenergic receptor antagonist (yohimbine; used as a pha

71 overflow for MA was enhanced by the alpha(2)-adrenergic receptor antagonist, yohimbine (1.0 microm),